Mezzion Pharma Statistics

Total Valuation

Mezzion Pharma has a market cap or net worth of KRW 1.11 trillion. The enterprise value is 1.09 trillion.

Market Cap	1.11T
Enterprise Value	1.09T

Important Dates

The next estimated earnings date is Thursday, May 15, 2025.

Earnings Date	May 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Mezzion Pharma has 30.01 million shares outstanding. The number of shares has increased by 5.62% in one year.

Current Share Class	30.01M
Shares Outstanding	30.01M
Shares Change (YoY)	+5.62%
Shares Change (QoQ)	+0.66%
Owned by Insiders (%)	9.57%
Owned by Institutions (%)	5.99%
Float	21.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	129.28
PB Ratio	24.17
P/TBV Ratio	25.05
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-55.77
EV / Sales	126.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-56.93

Financial Position

The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.04.

Current Ratio	1.57
Quick Ratio	1.12
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	-0.08
Interest Coverage	-47.54

Financial Efficiency

Return on equity (ROE) is -36.23% and return on invested capital (ROIC) is -16.05%.

Return on Equity (ROE)	-36.23%
Return on Assets (ROA)	-10.76%
Return on Invested Capital (ROIC)	-16.05%
Return on Capital Employed (ROCE)	-30.21%
Revenue Per Employee	506.57M
Profits Per Employee	-1.15B
Employee Count	17
Asset Turnover	0.10
Inventory Turnover	1.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -1.07% in the last 52 weeks. The beta is 0.39, so Mezzion Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	-1.07%
50-Day Moving Average	34,110.00
200-Day Moving Average	31,845.75
Relative Strength Index (RSI)	50.76
Average Volume (20 Days)	120,039

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mezzion Pharma had revenue of KRW 8.61 billion and -19.48 billion in losses. Loss per share was -653.04.

Revenue	8.61B
Gross Profit	1.91B
Operating Income	-14.30B
Pretax Income	-14.53B
Net Income	-19.48B
EBITDA	-13.34B
EBIT	-14.30B
Loss Per Share	-653.04

Full Income Statement

Balance Sheet

The company has 28.62 billion in cash and 1.62 billion in debt, giving a net cash position of 27.00 billion or 899.82 per share.

Cash & Cash Equivalents	28.62B
Total Debt	1.62B
Net Cash	27.00B
Net Cash Per Share	899.82
Equity (Book Value)	46.06B
Book Value Per Share	1,537.30
Working Capital	15.26B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -18.49 billion and capital expenditures -590.49 million, giving a free cash flow of -19.08 billion.

Operating Cash Flow	-18.49B
Capital Expenditures	-590.49M
Free Cash Flow	-19.08B
FCF Per Share	-635.84

Full Cash Flow Statement

Margins

Gross margin is 22.18%, with operating and profit margins of -166.05% and -226.17%.

Gross Margin	22.18%
Operating Margin	-166.05%
Pretax Margin	-168.77%
Profit Margin	-226.17%
EBITDA Margin	-154.93%
EBIT Margin	-166.05%
FCF Margin	n/a

Dividends & Yields

Mezzion Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.62%
Shareholder Yield	-5.62%
Earnings Yield	-1.75%
FCF Yield	-1.71%

Stock Splits

The last stock split was on April 5, 2022. It was a forward split with a ratio of 3.

Last Split Date	Apr 5, 2022
Split Type	Forward
Split Ratio	3

Scores

Mezzion Pharma has an Altman Z-Score of 19.76.

Altman Z-Score	19.76
Piotroski F-Score	n/a